T. Rowe Price Investment Management’s Aktis Oncology AKTS Stock Holding History

T. Rowe Price Investment Management’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38M	Buy	+2,123,812	New	+$41.2M	0.03%	395

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Investment Management's AKTS Position: Q1 2026 in Review

T. Rowe Price Investment Management opened a new position in Aktis Oncology (AKTS) in Q1 2026: 2,123,812 shares worth $38M. The stake represents 0.03% of the portfolio and ranks #395 among its holdings.

69 funds tracked by Wall St. Rank hold AKTS as of Q1 2026.

T. Rowe Price Investment Management held 2,123,812 shares of Aktis Oncology worth $38M as of Q1 2026.
Aktis Oncology was a new T. Rowe Price Investment Management position in Q1 2026.
Aktis Oncology made up 0.03% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #395 holding.
69 funds tracked by Wall St. Rank held Aktis Oncology as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.